Table 1 Baseline characteristics of the international validation cohort
From: Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts
Variables | All patients (n = 651) |
|---|---|
Age, years | 48.2 ± 16.0 |
Gender, % of men | 32.9% |
Body-mass index, kg/m2 | 22.4 ± 11.5 |
Dyspnea (mMRC) | 1.52 ± 1.0 |
Smoking (packs-year) | 4.81 ± 12.8 |
Sputum appearance, % | |
No sputum | 18,6% |
Mucous | 27.2% |
Mucopurulent | 35.2% |
Purulent | 19.0% |
Respiratory insufficiency, % | 16.9% |
Number of affected lobes | 3.3 ± 1.5 |
Aetiology % | |
Post-infective | 40.3% |
Idiopathic | 31.3% |
Primary ciliary diskinesia | 9.0% |
Airway diseasea | 5.1% |
Rheumatologic disease | 4.3% |
Other causes | 10.0% |
FEV1, % predicted | 54.7 ± 22.1 |
FVC, % predicted | 67.2 ± 20.3 |
Chronic colonization, % | |
Pseudomonas aeruginosa | 39.8% |
Exacerbations (previous year) | 1.12 ± 1.4 |
Hospitalizations (previous year) | 0.4 ± 0.8 |
Chronic treatment, % | |
Systemic antibiotics | 7.2% |
Inhaled antibiotics | 30.5% |
Macrolides | 17.3% |
Oral corticoids | 3.8% |
Comorbidities, % | |
Asthma | 10.0% |
Systemic arterial hypertension | 9.8% |
Pulmonary hypertension | 4.0% |
COPD | 3.7% |
Diabetes mellitus | 3.4% |
Chronic cardiac disease | 3.2% |
Death, % | 14.6% |